Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Dow
McKinsey
Colorcon
Baxter
Mallinckrodt

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,148,207

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,148,207 protect, and when does it expire?

Patent 7,148,207 protects OFORTA and is included in one NDA.

This patent has thirty-seven patent family members in thirty countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 7,148,207
Title:Oral fludara of high-purity formulation with quick release of active ingredient
Abstract:This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.
Inventor(s): Heil; Wolfgang (Stelle, DE), Tistam; Ulf (Wezembeek Oppem, BE), Lipp; Ralph (Berlin, DE), Tack; Johannes-Wilhelm (Berlin, DE)
Assignee: Schering Aktiengesellschaft (Berlin, DE)
Application Number:10/324,141
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 7,148,207

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sanofi Aventis Us OFORTA fludarabine phosphate TABLET;ORAL 022273-001 Dec 18, 2008 DISCN No No   Start Trial   Start Trial Y TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,148,207

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany101 64 510Dec 20, 2001

International Family Members for US Patent 7,148,207

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 037965   Start Trial
Austria 303797   Start Trial
Australia 2002349043   Start Trial
Brazil 0215265   Start Trial
Canada 2471396   Start Trial
China 1306929   Start Trial
China 1617713   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Dow
McKesson
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.